Replies to post #194161 on Zeev's Turnips Patch-No Politics (ZEEV)

[Zeev Hed]

They are raising another $50 MM, which should give them ample breathing room. And yes, if they have the real McCoy for Alzheimer, a market cap of around $300 MM is not yet "outrageous", but that "if" is quite big right now.

[jdaasoc]

RE AXYZ what ever it's symbol is

This Dr. Marvin Hausman guy beter be real scientist not a pink sheet quack.


Axonyx Acquires Controlling Interest in OXIS International; OXIS' Oxidative Stress Technologies Complement Axonyx' Neurodegenerative Therapeutic Program


--------------------------------------------------------------------------------
Tue Jan 20 09:15:00 2004 EST
PORTLAND, Ore., Jan 20, 2004 (BUSINESS WIRE) --
OXIS
International, Inc. (OTCBB:OXIS) (Nouveau Marche: OXIS) announced
today that Axonyx Inc. (Nasdaq:AXYX), a U.S.-based biophamaceutical
company, plans to acquire the controlling interest in OXIS through the
purchase of approximately 53% of the company's outstanding voting
stock.
Axonyx develops proprietary pharmaceutical compounds and new
technologies useful in the diagnosis and treatment of Alzheimer's
disease, human memory disorders, and prion-based illnesses such as Mad
Cow disease.
OXIS is a leading provider of research and diagnostic products
used for the treatment of diseases associated with oxidative stress.
OXIS' oxidative-stress biomarker technologies can provide insight into
central nervous system disorders, such as Alzheimer's disease, that
result in nerve cell injury and death.
Under the terms of the agreements with several OXIS shareholders,
Axonyx will acquire approximately 14 million shares of OXIS stock in
exchange for an aggregate of approximately 1.6 million shares of
unregistered Axonyx common stock. Together with shares of OXIS stock
currently held by Marvin S. Hausman, M.D., Axonyx Chairman and CEO,
Axonyx will control approximately 57% of OXIS voting stock.
"There is a strong synergistic fit between our oxidative stress
diagnostic technologies and the leading-edge work Axonyx is doing in
the treatment of diseases such as Alzheimer's," stated Ray R. Rogers,
Chairman and CEO of OXIS International. "OXIS plans to work
cooperatively with the Axonyx clinical research team to advance our
broad portfolio of products, including our anti-oxidant
nutraceuticals, Animal Health Profiling Program and therapeutic drug
development efforts. As a result, we believe that our combined areas
of expertise will enhance shareholder value for both companies."
"Scientists and clinicians are only now starting to appreciate the
key pathologic role that oxidative stress plays in many human diseases
and disorders, including but not limited to heart disease,
gastrointestinal disorders and Alzheimer's disease," stated Dr.
Hausman. "OXIS' diagnostic and therapeutic technologies can not only
be used potentially to treat patients, but can lead to greater
understanding of the pathophysiology of many of these diseases."
No immediate changes in OXIS operations are envisioned at this
time. OXIS will continue to operate from its worldwide headquarters in
Portland, Oregon.